Neuropeptide-2 receptor (y-2r) agonists and uses thereof

A neuropeptide-2 receptor agonist of the formula (I):

• wherein:
• X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa),
• Y is a substituted or unsubstituted alkyl, a substituted or unsubstituted lower alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted alkoxy, a poly(ethylene) glycol moiety, PEGm-SSA, PEGm-β-SBA, PEGm-SPA or PEGm-BTC,
• Y′ is H, a poly(ethylene) glycol moiety, PEGm-SSA, PEGm-β-SBA, PEGm-SPA or PEGm-BTC,
• R1 is Ile, Ala, (D) Ile, N-methyl Ile, Aib, 1-1Aic, 2-2 Aic, Ach or Acp,
• R2 is Lys, Ala, (D) Lys, NMelys, Nle or (Lys-Gly),
• R3 is Arg, Ala, (D)Arg, N-methyl Arg, Phe, 3,4,5-Trifluoro Phe or 2,3,4,5,6-Pentafluoro Phe,
• R4 is His, Ala, (D)His, N-methyl His, 4-MeOApc, 3-Pal or 4-Pal,
• R5 is Tyr, Ala, (D) Tyr, N-methyl Tyr, Trp, Tic, Bip, Dip, (1)Nal, (2)Nal, 3,4,5-TrifluoroPhe or 2,3,4,5,6-Pentafluoro Phe,
• R6 is Leu, Ala, (D)Leu or N-methyl Leu,
• R7 is Asn, Ala or (D)Asn,
• R8 is Leu or Trp,
• R9 is Val, Ala, (D) Val or N-methyl Val,
• R10 is Thr, Ala or N-methyl Thr,
• R11 is Arg, (D) Arg or N-methyl Arg,
• R12 is Gln or Ala,
• R13 is Arg, (D)Arg or N-methyl Arg,
• R14 is Tyr, (D) Tyr, N-methyl Tyr, modified-Tyr, Phe, modified-Phe or Trp, and
• m is 1 to 60 KDa,
• or a pharmaceutically acceptable salt thereof.